Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
VanEck Semiconductor ETF
SMH
Invesco Solar ETF
TAN
4
Direxion Daily Energy Bull 2X Shares ETF
ERX
5
The Technology Select Sector SPDR® Fund
XLK
US Stock MarketDetailed Quotes
Trevi Therapeutics (TRVI)
- 14.200
- -0.880-5.84%
Close May 15 16:00 ET
- 14.200
- 0.0000.00%
Post 16:10 ET
2.02BMarket Cap-44.38P/E (TTM)
14.990High14.060Low896.41KVolume14.820Open15.080Prev Close12.83MTurnover0.76%Turnover RatioLossP/E (Static)141.98MShares16.12052wk High11.72P/B1.67BFloat Cap5.38052wk Low--Dividend TTM117.51MShs Float16.120Historical High--Div Yield TTM6.17%Range %0.460Historical Low14.309Avg Price1Lot Size
TRVI Stock Chart
After-Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
TRVI Orderflow
Unit: --
TRVI Orderflow Trend
IntradayDayWeekMonth
No Data
Trevi Therapeutics (TRVI) News
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX)
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $30
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $21
Express News | Trevi Therapeutics Inc : Stifel Raises Target Price to $30 From $18
Clear Street Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $29
Trevi Therapeutics (TRVI) Stock Forum
$Trevi Therapeutics (TRVI.US)$ Press Release: Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dow Jones
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio(TM) (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (...
Dow Jones
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio(TM) (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (...
1
8
$Trevi Therapeutics (TRVI.US)$
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
by Globe Newswire
Follow
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough
First pivotal trial is on track to initiate in the second quarter of 2026, with the second pivotal trial expected to initi...
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
by Globe Newswire
Follow
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough
First pivotal trial is on track to initiate in the second quarter of 2026, with the second pivotal trial expected to initi...
1
$Trevi Therapeutics (TRVI.US)$ Trevi Therapeutics Announces Publication of Data From the Phase 2b IPF Chronic Cough Trial of Nalbuphine ER in the Journal of the American Medical Association (JAMA)
PR Newswire
3m
Statistically-significant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant cough reduction as early as Week 2, the first time point measured
Over 60% of nalbup...
PR Newswire
3m
Statistically-significant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant cough reduction as early as Week 2, the first time point measured
Over 60% of nalbup...
4
$Trevi Therapeutics (TRVI.US)$ Still to come soon! Could be catalyst!
The Company plans to participate in the following events: September 17-19: 2025 Leerink Partners Biopharma Summit
September 27-October 1: European Respiratory Society (ERS) Congress
The Company plans to participate in the following events: September 17-19: 2025 Leerink Partners Biopharma Summit
September 27-October 1: European Respiratory Society (ERS) Congress
2
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)
DongBei : Is it going to rise?
Trytosaveabit OP DongBei : Depends on volume
DongBei Trytosaveabit OP : Let's analyze GPUs. Why is there no movement?
DongBei :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP DongBei : There would be lots of movement up if it wasn’t for MMs manipulating the price! I mean today alone they sent 80% of todays open market volume off exchange to hold / drive down the price! It should be completely criminal!
View more comments...